International Journal of Urology最新文献_第5页

Bladder Preservation: An Overview of Novel Prospects and Limitations.

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-27 DOI: 10.1111/iju.70022

Mazyar Zahir, Chirag Doshi, Domenique Escobar, Siamak Daneshmand

引用次数: 0

Editorial Comment to "Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer".

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-27 DOI: 10.1111/iju.70031

Yoh Matsuoka

引用次数: 0

Editorial Comment on "Influence of Best Objective Response to First-Line Treatment on Survival Outcomes in Advanced Urothelial Carcinoma in the Era of Sequential Therapy With Enfortumab Vedotin".

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-27 DOI: 10.1111/iju.70029

Takashi Kobayashi

引用次数: 0

Editorial Comment on “South African Single Surgeon Experience: Comparison of Oncological Outcomes, Robot-Assisted Radical Prostatectomy Versus Open Perineal Radical Prostatectomy”

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-26 DOI: 10.1111/iju.70017

Cagri Akpinar

引用次数: 0

Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-25 DOI: 10.1111/iju.70019

Kazuhiro Suzuki, Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama, Fumiko Ueno, Hirotsugu Uemura

{"title":"Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.","authors":"Kazuhiro Suzuki, Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama, Fumiko Ueno, Hirotsugu Uemura","doi":"10.1111/iju.70019","DOIUrl":"https://doi.org/10.1111/iju.70019","url":null,"abstract":"The incidence of prostate cancer (PC) has recently increased in Japan. Androgen deprivation therapy (ADT) has been a key treatment in patients with castration-sensitive PC (CSPC); however, resistance typically emerges through multiple mechanisms, leading to metastatic castration-resistant PC (mCRPC). Taxane-based therapy (i.e., docetaxel, cabazitaxel) has been standard care in patients with mCRPC. New evidence supporting the addition of androgen receptor signaling inhibitors (ARSIs, e.g., enzalutamide, abiraterone) to docetaxel and ADT for patients with metastatic CSPC (mCSPC) raises questions about the role of taxane-based therapies and their optimal sequencing, as well as how to identify patients who may benefit from taxane-based therapy. Here we review the evidence on taxane-based therapy, including cabazitaxel, in the treatment of PC, with a focus on clinical and real-world evidence from Japan. Cabazitaxel has proven effective for patients with mCRPC who have a history of ARSI and docetaxel use, and it is preferable to a second alternative ARSI, as indicated in the CARD study. The safety profile of cabazitaxel (particularly, the incidence of neutropenia) can be managed through prophylactic use of granulocyte colony-stimulating factor, as well as a lower dosage and possibly variation of the dosage interval. However, a certain dose intensity is required because neutropenia has been identified as a potential prognostic indicator for treatment effectiveness. In the ARSI era for mCSPC, evidence on mCRPC treatment sequencing is limited. A better understanding of PC biology and the collection of real-world data is essential for effective treatment and improved safety-benefit outcomes.","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations on the Optimal Imaging for Prostate Cancer Diagnosis.

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-19 DOI: 10.1111/iju.70016

Fumihiko Urabe, Shoji Kimura

引用次数: 0

Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer.

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-19 DOI: 10.1111/iju.70013

Po-Fan Hsieh, Jun Naruse, Soichiro Yuzuriha, Tatsuya Umemoto, Chi-Ping Huang, Sunao Shoji

{"title":"Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer.","authors":"Po-Fan Hsieh, Jun Naruse, Soichiro Yuzuriha, Tatsuya Umemoto, Chi-Ping Huang, Sunao Shoji","doi":"10.1111/iju.70013","DOIUrl":"https://doi.org/10.1111/iju.70013","url":null,"abstract":"Objectives: To test the feasibility of combining percentage prostate-specific antigen (PSA) reduction and multiparametric magnetic resonance imaging (mpMRI) to determine the clinical scenario in which follow-up biopsy could be avoided after focal therapy (FT) with high-intensity focused ultrasound (HIFU) for prostate cancer.Methods: We reviewed 90 men treated with FT. Percentage PSA reduction was calculated by PSA nadir within postoperative 6 months. mpMRI was arranged at postoperative 6 months, followed by routine biopsy. Logistic regression analyses were performed to identify predictors for clinically significant prostate cancer (csPC) on follow-up biopsy. Receiver operating characteristic curve analysis was done to assess the area under the curve (AUC). The diagnostic performance of percentage PSA reduction and mpMRI to predict csPC was also calculated.Results: Eight patients had csPC recurrence. Percentage PSA reduction and Prostate Imaging-Reporting and Data System (PI-RADS) ≥ 3 at postoperative 6 months were predictors for csPC (p = 0.033 and p = 0.02, respectively). The AUC of mpMRI, percentage PSA reduction, and their combination were 0.95, 0.816, and 0.982, respectively. The sensitivity, specificity, positive predictive value, and negative predictive value of PSA reduction < 70% and PI-RADS ≥ 3 to predict csPC were 87.5%, 69.5%, 21.9%, 98.3%, and 87.5%, 96.3%, 70%, 98.8%, respectively. Using the criteria of PSA reduction < 70% or PI-RADS ≥ 3 to determine biopsy candidates could avoid 60% of biopsies, without missing csPC.Conclusion: For patients whose PSA reduction > 70% and PI-RADS < 3, we suggested avoiding routine biopsy at 6 months after FT with HIFU.","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Comment on the Overuse of Imaging in Prostate Cancer Staging.

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-17 DOI: 10.1111/iju.70015

Hiroaki Iwamoto, Kouji Izumi, Atsushi Mizokami

引用次数: 0

Evaluating Risk Factors for Pathological Upstaging in Upper Tract Urothelial Carcinoma.

IF 1.8 3区医学

International Journal of Urology Pub Date : 2025-02-14 DOI: 10.1111/iju.70011

Fumihiko Urabe, Ryotaro Yamaguchi

引用次数: 0

This Issue 32–3